Editorial
Osimertinib in untreated epidermal growth factor receptor (EGFR)- mutated advanced non-small cell lung cancer
Abstract
Lung cancer remains the leading cause of cancer-related deaths worldwide (1). Non-small cell lung cancer (NSCLC) accounts for approximately 80–85% of all cases of lung cancer and is commonly diagnosed at an advanced stage of disease.
